Multiple Myeloma and Plasma Cell Neoplasm Clinical Trial
Official title:
A Phase II Trial of CC-4047 Plus Dexamethasone in Patients With Relapsed of Refractory Multiple Myeloma or Amyloidosis
RATIONALE: Biological therapies, such as CC-4047, may stimulate the immune system in
different ways and stop cancer cells from growing. Dexamethasone and CC-4047 may stop the
growth of cancer cells by blocking blood flow to the cancer. Giving CC-4047 together with
dexamethasone may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving CC-4047 together with dexamethasone
works in treating patients with relapsed or refractory multiple myeloma or amyloidosis.
OBJECTIVES:
- To assess the response rate and duration of remission with low-dose CC-4047 plus
dexamethasone in patients with relapsed or refractory multiple myeloma or amyloidosis.
- To assess the toxicity of CC-4047 plus dexamethasone in this patient population.
- To assess in an expansion cohort the response rate with an increase in CC-4047 dose
among patients who fail to respond adequately to the initial starting dose following the
first 2 courses of treatment.
- To assess the response rate and duration of remission with CC-4047 plus dexamethasone in
patients with lenalidomide resistant or refractory multiple myeloma.
- To assess the response rate and duration of remission with CC-4047 plus dexamethasone in
patients with previously treated light chain amyloidosis.
- To assess the response rate and duration of remission with low- and high-dose CC-4047
plus dexamethasone in patients with lenalidomide and bortezomib refractory multiple
myeloma.
- To assess the response rate and duration of remission with high-dose CC-4047 plus
dexamethasone in patients with relapsed or refractory myeloma who received ≤ 3 treatment
regimens.
OUTLINE: Patients are grouped according to disease status (relapsed/refractory myeloma
[closed to accrual as of 8/5/2008] vs lenalidomide resistant/refractory myeloma [closed to
accrual as of 4/2/2009] vs previously treated light chain amyloidosis vs lenalidomide and
bortezomib resistant/refractory myeloma {low-dose/day}[closed to accrual as of 11/20/09] vs
lenalidomide and bortezomib resistant/refractory myeloma (high-dose/day) vs
relapsed/refractory myeloma {high-dose/day}).
Patients receive oral CC-4047 on days 1-28 and oral dexamethasone on days 1, 8, 15, and 22.
Treatment repeats every 28 days in the absence of disease progression or unacceptable
toxicity.
After completion of study treatment, patients are followed for 4 weeks and then at 6 months.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00568880 -
Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
| Recruiting |
NCT01137825 -
Registry of Older Patients With Cancer
|
||
| Suspended |
NCT00935090 -
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
|
N/A | |
| Completed |
NCT00898066 -
S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood Disease
|
N/A | |
| Terminated |
NCT00608517 -
Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil
|
N/A | |
| Completed |
NCT00478075 -
Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
| Completed |
NCT00313625 -
Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma
|
Phase 2 | |
| Completed |
NCT00951626 -
A Standardized Nursing Intervention Protocol for HCT Patients
|
N/A | |
| Completed |
NCT00301951 -
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
|
Phase 1 | |
| Terminated |
NCT00369291 -
CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant
|
Phase 1 | |
| Completed |
NCT00937183 -
Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma
|
N/A | |
| Completed |
NCT00049374 -
Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 2 | |
| Completed |
NCT00004072 -
O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma
|
Phase 2 | |
| Completed |
NCT00003396 -
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
| Completed |
NCT00003399 -
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
|
Phase 2 | |
| Completed |
NCT00003398 -
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
|
Phase 4 | |
| Active, not recruiting |
NCT00003163 -
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers
|
Phase 2 | |
| Terminated |
NCT00005641 -
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
|
Phase 2 | |
| Active, not recruiting |
NCT00002599 -
Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma
|
Phase 3 |